Compare Crossject SA with Similar Stocks
Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -9.83% of over the last 5 years
- The company has a negative book value of Rs 2.05 crore
2
Flat results in Jun 25
3
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.24%
0%
-9.24%
6 Months
-27.25%
0%
-27.25%
1 Year
-7.02%
0%
-7.02%
2 Years
-5.64%
0%
-5.64%
3 Years
-39.79%
0%
-39.79%
4 Years
-2.36%
0%
-2.36%
5 Years
-30.69%
0%
-30.69%
Crossject SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-9.83%
EBIT to Interest (avg)
-12.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-3.10
Sales to Capital Employed (avg)
0.04
Tax Ratio
18.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-50.03
EV to EBIT
-8.85
EV to EBITDA
-14.41
EV to Capital Employed
12.26
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-138.48%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-10.30
-9.90
-4.04%
Interest
1.40
0.80
75.00%
Exceptional Items
-0.20
0.60
-133.33%
Consolidate Net Profit
-12.80
-8.60
-48.84%
Operating Profit Margin (Excl OI)
0.00%
-99,351.70%
9,935.17%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -100.00% vs -90.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -48.84% vs 23.21% in Dec 2023
About Crossject SA 
Crossject SA
Pharmaceuticals & Biotechnology
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject’s first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
Company Coordinates 
Company Details
Parc Mazen-Sully, 6 Rue Pauline Kergomard DIJON None : 21000
Registrar Details






